Paul Seid
About Paul A. Seid
Independent director of Intellinetics, Inc. (INLX). Age 76. Joined the INLX board on June 22, 2023; standing for re‑election in 2025. Background includes CEO of RST Automation (hospital robotics) since 2013 and President of Strategic Data Marketing for ~18 years; BA in Political Science from Queens College (CUNY), 1968 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| RST Automation | Chief Executive Officer | 2013–present | Leads hospital robotics device company |
| Strategic Data Marketing | President | ~2007–present (18 years) | Research/data collection; founded/bought/sold 20+ companies globally |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BGSF Inc. (NYSE:BGSF) | Director | Since 2014 | Not disclosed in INLX filings |
| BioVentrix (private) | Director | Since 2010 | Not disclosed in INLX filings |
Board Governance
- Independence: Determined independent under NYSE American standards; one of INLX’s independent directors (alongside Guttilla and Jaworski) .
- Committee assignments: Audit Committee member; current committee composition is Guttilla (Chair), Seid, Jaworski . In 2024, Audit Committee was Guttilla (Chair), Kahn, Seid (Kahn resigned Feb 18, 2025) .
- Attendance: Board held 4 meetings in 2024; each director attended ≥88% of Board/committee meetings, aggregate 98% . Annual stockholder meeting attendance last year: 16% of directors .
- Executive sessions: Independent directors hold executive sessions as needed without management present .
- Risk oversight: Audit Committee oversees financial reporting/internal controls and reviews related‑party transactions .
Fixed Compensation
| Year | Cash Retainer (USD) | Committee Chair Fees (USD) | Meeting Fees | Notes |
|---|---|---|---|---|
| 2023 | $10,000 | None disclosed | None | Director stock award $20,000 fully vested |
| 2024 | $25,000 | None disclosed | None | Option awards fair value $40,289; fully vested at grant; Total $70,289 |
| 2025 Plan (approved 4/1/2025) | $27,000 base; +$15,000 Board Chair; +$15,000 Audit Chair; +$5,000 Comp Chair | As listed | No meeting fees | Equity: 4,500 fully vested NQ options; +4,500 options for Board Chair |
Performance Compensation
- Director equity (structure rather than performance metrics): Annual non‑employee director equity grants are fully vested non‑qualified stock options; grant sizes updated in 2025 plan. No performance‑conditioned director equity disclosed (options vest at grant) .
| Metric | 2023 Director Equity | 2024 Director Equity | 2025 Plan Director Equity |
|---|---|---|---|
| Form | Stock award (shares) | Option awards (fully vested) | Fully vested NQ options |
| Grant size (Paul Seid) | $20,000 fair value | $40,289 fair value | 4,500 options (base plan; Board Chair receives +4,500) |
| Vesting | Fully vested at grant | Fully vested at grant | Fully vested at grant |
Other Directorships & Interlocks
- External public board: BGSF Inc. (NYSE:BGSF), director since 2014 .
- Private boards: BioVentrix (medical devices), director since 2010 .
- Potential interlocks at INLX: Taglich Brothers retains issuer‑paid research services ($18,000/yr); Michael and Robert Taglich are significant holders and principals of Taglich Brothers. No related‑party transactions disclosed involving Seid .
Expertise & Qualifications
- Growth/operator background: Founded/bought/sold 20+ companies across geographies; CEO experience in healthcare robotics; research/data businesses .
- Financial literacy: Audit Committee members deemed financially literate by Board; Audit Committee chaired by an audit committee financial expert (Guttilla) .
- Governance orientation: Independent director with Audit Committee duties including oversight of financial reporting, internal controls, and related‑party reviews .
Equity Ownership
| Holder | Shares Beneficially Owned | % Outstanding | Derivatives/Status |
|---|---|---|---|
| Paul A. Seid | 195,523 | 4.53% | Includes 6,000 stock options exercisable within 60 days of April 25, 2025 |
- Hedging/pledging: Directors/officers prohibited from hedging and generally from pledging company securities; no pledging reported for Seid .
Governance Assessment
- Alignment signals: Independent status and Audit Committee membership support board effectiveness; prohibition on hedging/pledging reduces misalignment risk .
- Attendance/engagement: Board/committee attendance was strong in 2024 (≥88% for each director; aggregate 98%), suggesting engagement; note low attendance at annual meeting (16%) is a mild optics issue but not specific to Seid .
- Compensation mix trend: Shift from stock awards (2023) to fully vested options (2024–2025 plan). Options are at‑risk with respect to share price but lack performance vesting; cash retainer modest. No meeting fees, with chair uplifts centralized—Seid currently a member, not chair .
- Conflicts/red flags: No related‑party transactions disclosed for Seid. Broader board exposure to Taglich Brothers (fees and ownership) is a potential governance sensitivity; Audit Committee charter explicitly requires review/approval of related‑person transactions, and Seid participates in that oversight .
- Tenure/experience: ~2 years on INLX board, deep operating experience in robotics and data businesses, and public board service at BGSF—useful for strategy and oversight .
